Paying for care · Read past the headline
Ask for the full bill in writing. A medicine price and a care plan price are different things. Keep the ongoing cost beside the first offer.
Wegovy injections, approved for losing weight and keeping it off, contain the medicine ingredient semaglutide.
Medicine only · Cash outside insurance
As of September 2026, the maker’s usual cash price for semaglutide (Wegovy) injection was $349 per monthly box.
Wegovy HD is the product name for a higher-strength version of the injection. Its monthly box cost $399 as of September 2026.
Strength is the amount of medicine in a product. Ask which product the quoted price covers.
As of September 2026, new patients paying outside insurance could pay $199 for each of their first two monthly boxes of Wegovy injections.
That is $398 for both months together. The offer covered only boxes marked 0.25 mg or 0.5 mg; mg means milligrams, which measure the amount of medicine.
These numbers identify the price offer. Ask the person prescribing which product you need.
Those introductory terms run through December 31, 2026.
Self-pay means paying outside insurance. Under these cash offers, the spending does not count toward an insurance deductible or out-of-pocket maximum.
A deductible is the amount paid before a plan starts paying for covered care. Ask the insurer how its own plan works.
A yearly out-of-pocket cap limits what you pay for covered care.
Myth to test
What holds up
Some online weight-care services bill separately for medicine and charge a monthly care fee, as of September 2026. Do not assume a Seattle clinic or an online service includes the medicine in its fee.
Ask for care visits, medicine, tests, supplies, and delivery to be listed together. Mark each item as included or extra.
Keep the standard ongoing rate, the offer’s end, any prepayment, and the cancellation terms in the same note.
Ask the plan whether it covers the exact product for the condition being treated. Ask about any approval needed before payment.
That step is called prior authorization: the insurer reviews the request before it agrees to pay.
Medicines used only for weight loss are excluded from ordinary Medicare drug coverage, as of September 2026.
Medicare drug plans may cover these medicines for other accepted uses, such as type 2 diabetes or lowering heart attack and stroke risk in eligible patients.
Zepbound may qualify for adults with obesity and moderate or severe sleep apnea caused by blocked breathing. Each plan still decides whether it pays.
Zepbound injections, also approved for losing weight and keeping it off, contain the medicine ingredient tirzepatide.
A copay is your share of the bill.
Semaglutide and tirzepatide are often called GLP-1 medicines. GLP-1 occurs naturally as a hormone and affects blood sugar and appetite; these medicines act like that hormone.
As of September 2026, covered products are Wegovy injections or tablets, Zepbound in the KwikPen device, and Foundayo tablets containing orforglipron, a weight-loss medicine.
For Zepbound, other pen devices and the small bottles called vials are not covered by this programme.
As of September 2026, the $50 programme requires a qualifying Medicare drug plan and an age of at least 18.
A separate Part D plan for drugs can qualify, as can a Medicare Advantage plan that includes both care coordination and drug coverage. Some other plan types do not qualify on their own.
Ask your plan: Can I use the Medicare GLP-1 Bridge with this exact plan?
The person prescribing must check your body mass index (BMI), calculated from your height and weight, and your health when treatment began.
As of September 2026, one of these health rules must be met:
Bring this list to the person prescribing; ask them to confirm the exact diagnosis and measurements.
Bridge use in 2026 is unavailable if your Part D plan already paid for a GLP-1 medicine earlier in 2026.
As of September 2026, Medicare had not announced the rule about earlier coverage for 2027.
People with type 2 diabetes or moderate or severe obstructive sleep apnea cannot use this programme. Obstructive sleep apnea means breathing is blocked during sleep.
The Bridge also excludes people with a fatty-liver illness called MASH if it has caused moderate or advanced scarring without cirrhosis. Cirrhosis means extensive liver scarring.
These diagnoses go through the ordinary Medicare drug plan route. Having just any fatty-liver diagnosis does not rule you out; ask the person prescribing to check the exact diagnosis.
A prescription for lowering heart attack and stroke risk also goes to your ordinary drug plan instead.
The Bridge requires a prescription and approval before payment, plus a continuing plan for physical activity and food.
Its copay does not count toward the ordinary Medicare drug deductible or yearly out-of-pocket cap, as of September 2026.
A compounded medicine is one that a doctor or pharmacist makes to order.
As of September 2026, the law restricts regularly making copies of medicines already sold ready-made, or making large amounts of those copies.
An exception can apply if the person prescribing identifies a change to the medicine that makes an important difference for your medical care. A lower price alone is not enough.
A medical reason might be needing a version without a dye you are allergic to.
Neither semaglutide injections nor tirzepatide was on the national shortage list as of September 2026.
Ask what medical need the compounded version meets.
Next: look for gaps in the offer